Targeted Temperature Management (TTM)

Introduction

Targeted Temperature Management (TTM), previously termed therapeutic hypothermia, is a neuroprotective strategy used in patients following cardiac arrest and selected hypoxic-ischemic brain injuries. 

Why TTM is Required — Pathophysiological Basis

Post–Cardiac Arrest Brain Injury (PCABI)

Brain injury after cardiac arrest occurs via two major mechanisms:

1. Primary Injury

Occurs during:

  • No-flow phase (cardiac arrest)
  • Low-flow phase (CPR)

Mechanisms:

  • Global cerebral ischemia
  • ATP depletion
  • Loss of ion gradients
  • Cytotoxic edema


2. Secondary Reperfusion Injury

Occurs after ROSC and is the main target of TTM

Mechanisms:

🔹 Excitotoxicity

🔹 Oxidative Stress

🔹 Inflammatory Cascade

🔹 Cerebral Edema

🔹 Mitochondrial Dysfunction


How TTM Provides Neuroprotection

TTM reduces injury via:

Mechanism

Effect

↓ Cerebral metabolic rate

~6–8% reduction per °C

↓ Excitatory neurotransmitters

↓ glutamate

↓ Free radical production

↓ oxidative injury

↓ Inflammation

↓ cytokine release

↓ ICP

Reduced cerebral edema

↓ Apoptosis

Preserves neuronal survival


Indications of TTM

Primary Indication (Strong Evidence)

Adult Post Cardiac Arrest Patients with ROSC and Coma

Guideline Preferred Candidates:

  • Out-of-hospital cardiac arrest (OHCA)
  • In-hospital cardiac arrest (IHCA)
  • Persistent coma (GCS motor ≤5)
  • Both shockable and non-shockable rhythms


Evidence Supporting Use

Landmark Trials

🔹 HACA Trial (2002)

  • Demonstrated improved neurological outcomes
  • Temperature: 32–34°C

🔹 Bernard Trial (2002)

  • Confirmed survival benefit

🔹 TTM Trial (2013)

  • Compared 33°C vs 36°C
  • Similar outcomes
  • Highlighted importance of fever prevention

🔹 TTM2 Trial (2021)

  • Compared hypothermia vs strict normothermia
  • No mortality difference
  • Reinforced fever avoidance as key goal


Current Guideline Recommendations (AHA 2020 / ERC 2021 / ILCOR 2022–24)

👉 Maintain 32–36°C for at least 24 hours
👉 Prevent fever (>37.7°C) for 72 hours


Other Possible Indications (Weaker Evidence)

  • Neonatal hypoxic ischemic encephalopathy
  • Refractory intracranial hypertension (selected cases)
  • Severe traumatic brain injury (investigational)


Contraindications

Absolute

  • Active uncontrolled bleeding
  • Severe hemodynamic instability refractory to support
  • DNR / expected futility

Relative

  • Severe sepsis
  • Pregnancy
  • Coagulopathy
  • Pre-existing terminal illness


Target Temperature Selection

Temperature

When Preferred

32–34°C

Younger patients, severe brain injury, prolonged downtime

35–36°C

Elderly, bleeding risk, shock

👉 Modern guidelines allow any target between 32–36°C
👉 Consistency is more important than exact number


Phases of Targeted Temperature Management

Phase 1 — Induction Phase

Goal: Rapid cooling to target temperature

Methods of Cooling

Surface Cooling Techniques

Includes:

  • Cooling blankets
  • Gel pad cooling systems
  • Ice packs
  • Cold saline infusion (limited role now)

Advantages:

  • Easy availability
  • Non-invasive

Disadvantages:

  • Slower cooling
  • Temperature fluctuations
  • Skin injury risk


Intravascular Cooling

Includes:

  • Central venous cooling catheters
  • Automated feedback systems

Advantages:

  • Precise temperature control
  • Faster cooling
  • Less shivering variability

Disadvantages:

  • Invasive
  • Thrombosis risk
  • Infection risk


Cooling Rate- 1–2°C per hour, Achieve target within 4–6 hours

Phase 2 — Maintenance Phase

Duration: Minimum 24 hours

Goals:

  • Maintain stable target temperature
  • Prevent shivering
  • Maintain organ perfusion


Phase 3 — Rewarming Phase

Rewarming Rate: 0.15–0.25°C per hour(Max 0.5°C/hr)

Rapid rewarming causes:

  • ICP spikes
  • Electrolyte shifts
  • Vasodilation
  • Hemodynamic collapse


Phase 4 — Normothermia / Fever Prevention

Continue:
👉 Maintain <37.7°C for 72 hours

Monitoring During TTM

Core Temperature Monitoring Sites

Preferred sites:

  • Esophageal probe
  • Bladder probe
  • Pulmonary artery catheter (gold standard)
  • Rectal probe (least accurate)

Shivering — Major Barrier to TTM

Why Shivering is Harmful

  • Increases metabolic rate
  • Increases oxygen consumption
  • Raises ICP
  • Counteracts cooling


Shivering Management Protocol (Stepwise)

Step 1: Non-pharmacologic

  • Skin counter-warming
  • Adequate analgesia
  • Sedation


Step 2: Pharmacologic

Sedatives

  • Propofol
  • Midazolam

Analgesics

  • Fentanyl
  • Remifentanil

Anti-shivering drugs

  • Magnesium infusion
  • Dexmedetomidine
  • Buspirone


Step 3: Neuromuscular Blockade

Used when:

  • Refractory shivering
  • Ventilator dyssynchrony

Common:

  • Cisatracurium
  • Vecuronium


Systemic Physiological Effects of TTM

Cardiovascular Effects

Early Hypothermia

  • Bradycardia (physiologic)
  • Increased SVR
  • Reduced cardiac output

Severe Hypothermia (<30°C)

  • Arrhythmias
  • QT prolongation


Respiratory Effects

  • Reduced CO₂ production
  • ABG interpretation must consider temperature correction


Metabolic Effects

Electrolyte Changes

Phase

Changes

Cooling

Hypokalemia, hypomagnesemia

Rewarming

Rebound hyperkalemia


Glucose

  • Insulin resistance
  • Hyperglycemia common


Coagulation Effects

  • Platelet dysfunction
  • Reduced clotting factor activity

Usually mild at 32–36°C


Renal Effects

  • Cold diuresis
  • Electrolyte wasting


Drug Pharmacokinetics

Hypothermia:

  • Reduces hepatic metabolism
  • Reduces renal clearance
  • Drug accumulation risk


Sedation and Analgesia Strategy

Goal:

  • Prevent shivering
  • Provide ventilator synchrony
  • Avoid over-sedation during neuro-prognostication

Preferred agents:

  • Propofol
  • Dexmedetomidine
  • Short-acting opioids


Hemodynamic Management During TTM

Targets:

  • MAP ≥65 mmHg (often higher 70–75 mmHg in PCABI)
  • Optimize oxygen delivery
  • Avoid hypotension

Preferred vasopressors:

  • Norepinephrine
  • Vasopressin adjunct


Ventilator Strategy During TTM

Maintain:

  • Normoxia (SpO₂ 94–98%)
  • Normocapnia (PaCO₂ 35–45 mmHg)

Avoid:

  • Hyperoxia → oxidative injury
  • Hypocapnia → cerebral vasoconstriction


Complications of TTM

Early Complications

  • Arrhythmias
  • Coagulopathy
  • Electrolyte disturbances
  • Insulin resistance


Late Complications

  • Infection risk
  • Skin injury
  • Venous thrombosis
  • Drug accumulation


Neuroprognostication During TTM

Guidelines: Delay neuroprognostication until:

  • ≥72 hours after ROSC
  • After rewarming
  • After sedation clearance

Reason:Hypothermia + sedation produce false poor prognostic signs.


Scroll to Top